The overarching experimental design is depicted in Figure . On day 1, each cell type was seeded on uniquely colored cell carriers (Huh7 on white, THP1 on red, and LX2 on blue). On day 2, the Huh7 ...
Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck. Mechanisms of resistance to anti-PD1 ...
The hiFlow in vitro platform. a Schematic of the hiFlow chip (backside view), with the components of the microfluidic network highlighted in the design. Each chip hosts two microfluidic networks and ...
For those considering adding Organ-on-a-chip (OOC) technology into the workflow, it may be unclear where to start. Firstly, using a commercially available solution, such as CN Bio's PhysioMimix ®, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results